CN101742926A - 用于改善脑功能的脂质组合物 - Google Patents
用于改善脑功能的脂质组合物 Download PDFInfo
- Publication number
- CN101742926A CN101742926A CN200880024527A CN200880024527A CN101742926A CN 101742926 A CN101742926 A CN 101742926A CN 200880024527 A CN200880024527 A CN 200880024527A CN 200880024527 A CN200880024527 A CN 200880024527A CN 101742926 A CN101742926 A CN 101742926A
- Authority
- CN
- China
- Prior art keywords
- lipid components
- weight
- acid
- aforementioned
- lipid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000002632 lipids Chemical class 0.000 title claims abstract description 99
- 230000003925 brain function Effects 0.000 title claims abstract description 28
- 239000000203 mixture Substances 0.000 title claims description 55
- FUZZWVXGSFPDMH-UHFFFAOYSA-N n-hexanoic acid Natural products CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 claims abstract description 32
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 claims abstract description 20
- 235000020673 eicosapentaenoic acid Nutrition 0.000 claims abstract description 13
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 claims abstract description 11
- 235000020661 alpha-linolenic acid Nutrition 0.000 claims abstract description 11
- 229960005135 eicosapentaenoic acid Drugs 0.000 claims abstract description 11
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 claims abstract description 11
- 229960004488 linolenic acid Drugs 0.000 claims abstract description 10
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 claims description 39
- 239000002253 acid Substances 0.000 claims description 25
- 125000001931 aliphatic group Chemical group 0.000 claims description 22
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 claims description 19
- 239000000835 fiber Substances 0.000 claims description 19
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 claims description 19
- 229940045145 uridine Drugs 0.000 claims description 19
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 claims description 12
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 claims description 11
- UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 claims description 10
- UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 claims description 10
- 208000014644 Brain disease Diseases 0.000 claims description 6
- 230000003412 degenerative effect Effects 0.000 claims description 6
- 229940035893 uracil Drugs 0.000 claims description 6
- 239000002773 nucleotide Substances 0.000 claims description 5
- 125000003729 nucleotide group Chemical group 0.000 claims description 5
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 5
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 claims description 4
- 208000012902 Nervous system disease Diseases 0.000 claims description 4
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 claims description 4
- 230000001149 cognitive effect Effects 0.000 claims description 4
- 150000002148 esters Chemical class 0.000 claims description 4
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 claims description 4
- 229910019142 PO4 Inorganic materials 0.000 claims description 3
- 208000027418 Wounds and injury Diseases 0.000 claims description 3
- 208000014674 injury Diseases 0.000 claims description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 3
- 239000010452 phosphate Substances 0.000 claims description 3
- 230000008733 trauma Effects 0.000 claims description 3
- 229930024421 Adenine Natural products 0.000 claims description 2
- 208000024827 Alzheimer disease Diseases 0.000 claims description 2
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 claims description 2
- 229930010555 Inosine Natural products 0.000 claims description 2
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 claims description 2
- 206010022489 Insulin Resistance Diseases 0.000 claims description 2
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 claims description 2
- 206010039966 Senile dementia Diseases 0.000 claims description 2
- 229960000643 adenine Drugs 0.000 claims description 2
- GFFGJBXGBJISGV-UHFFFAOYSA-N adenyl group Chemical group N1=CN=C2N=CNC2=C1N GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 claims description 2
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims description 2
- 206010012601 diabetes mellitus Diseases 0.000 claims description 2
- 229960003786 inosine Drugs 0.000 claims description 2
- 235000020778 linoleic acid Nutrition 0.000 claims description 2
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 claims description 2
- 150000007523 nucleic acids Chemical class 0.000 claims description 2
- 108020004707 nucleic acids Proteins 0.000 claims description 2
- 102000039446 nucleic acids Human genes 0.000 claims description 2
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 claims description 2
- 229940104230 thymidine Drugs 0.000 claims description 2
- 230000001988 toxicity Effects 0.000 claims description 2
- 231100000419 toxicity Toxicity 0.000 claims description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 2
- 150000001735 carboxylic acids Chemical class 0.000 claims 1
- 239000000194 fatty acid Substances 0.000 abstract description 10
- 235000014113 dietary fatty acids Nutrition 0.000 abstract description 8
- 229930195729 fatty acid Natural products 0.000 abstract description 8
- 150000004665 fatty acids Chemical class 0.000 abstract description 8
- WWZKQHOCKIZLMA-UHFFFAOYSA-N Caprylic acid Natural products CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 abstract description 7
- 150000004667 medium chain fatty acids Chemical class 0.000 abstract description 7
- OBETXYAYXDNJHR-UHFFFAOYSA-N alpha-ethylcaproic acid Natural products CCCCC(CC)C(O)=O OBETXYAYXDNJHR-UHFFFAOYSA-N 0.000 abstract 1
- GONOPSZTUGRENK-UHFFFAOYSA-N benzyl(trichloro)silane Chemical compound Cl[Si](Cl)(Cl)CC1=CC=CC=C1 GONOPSZTUGRENK-UHFFFAOYSA-N 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 19
- MBMBGCFOFBJSGT-KUBAVDMBSA-N docosahexaenoic acid Natural products CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 13
- SBJKKFFYIZUCET-JLAZNSOCSA-N Dehydro-L-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(=O)C1=O SBJKKFFYIZUCET-JLAZNSOCSA-N 0.000 description 12
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 12
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 12
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 12
- 150000001720 carbohydrates Chemical class 0.000 description 11
- 235000014633 carbohydrates Nutrition 0.000 description 11
- 239000007788 liquid Substances 0.000 description 10
- 230000001079 digestive effect Effects 0.000 description 9
- 235000018102 proteins Nutrition 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- 210000004556 brain Anatomy 0.000 description 8
- 230000003203 everyday effect Effects 0.000 description 8
- 239000011573 trace mineral Substances 0.000 description 8
- 235000013619 trace mineral Nutrition 0.000 description 8
- 229940088594 vitamin Drugs 0.000 description 8
- 229930003231 vitamin Natural products 0.000 description 8
- 235000013343 vitamin Nutrition 0.000 description 8
- 239000011782 vitamin Substances 0.000 description 8
- 210000004958 brain cell Anatomy 0.000 description 7
- 239000003921 oil Substances 0.000 description 7
- 235000019198 oils Nutrition 0.000 description 7
- 150000003722 vitamin derivatives Chemical class 0.000 description 7
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 6
- 229960000304 folic acid Drugs 0.000 description 6
- 235000019152 folic acid Nutrition 0.000 description 6
- 239000011724 folic acid Substances 0.000 description 6
- 230000007062 hydrolysis Effects 0.000 description 6
- 238000006460 hydrolysis reaction Methods 0.000 description 6
- 229910052500 inorganic mineral Inorganic materials 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 235000016709 nutrition Nutrition 0.000 description 6
- 230000035764 nutrition Effects 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 6
- 235000019158 vitamin B6 Nutrition 0.000 description 6
- 239000011726 vitamin B6 Substances 0.000 description 6
- 229940011671 vitamin b6 Drugs 0.000 description 6
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 230000000857 drug effect Effects 0.000 description 5
- 230000033001 locomotion Effects 0.000 description 5
- -1 palmitic medium chain fatty acid Chemical class 0.000 description 5
- 150000003626 triacylglycerols Chemical class 0.000 description 5
- 125000004432 carbon atom Chemical group C* 0.000 description 4
- 229960004203 carnitine Drugs 0.000 description 4
- ASARMUCNOOHMLO-WLORSUFZSA-L cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2s)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O ASARMUCNOOHMLO-WLORSUFZSA-L 0.000 description 4
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 4
- 150000002576 ketones Chemical class 0.000 description 4
- 239000011707 mineral Substances 0.000 description 4
- 235000010755 mineral Nutrition 0.000 description 4
- 229920005594 polymer fiber Polymers 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 206010012289 Dementia Diseases 0.000 description 3
- 229920002774 Maltodextrin Polymers 0.000 description 3
- 208000030886 Traumatic Brain injury Diseases 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 229940126534 drug product Drugs 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 210000000107 myocyte Anatomy 0.000 description 3
- 229920001542 oligosaccharide Polymers 0.000 description 3
- 150000002482 oligosaccharides Chemical class 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- ODIGIKRIUKFKHP-UHFFFAOYSA-N (n-propan-2-yloxycarbonylanilino) acetate Chemical compound CC(C)OC(=O)N(OC(C)=O)C1=CC=CC=C1 ODIGIKRIUKFKHP-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 206010003694 Atrophy Diseases 0.000 description 2
- 235000016068 Berberis vulgaris Nutrition 0.000 description 2
- 241000335053 Beta vulgaris Species 0.000 description 2
- 208000032928 Dyslipidaemia Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- 229920002907 Guar gum Polymers 0.000 description 2
- 239000005913 Maltodextrin Substances 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 230000003466 anti-cipated effect Effects 0.000 description 2
- 230000037444 atrophy Effects 0.000 description 2
- 230000037058 blood plasma level Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 239000005018 casein Substances 0.000 description 2
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 2
- 235000021240 caseins Nutrition 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000003920 cognitive function Effects 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 150000001991 dicarboxylic acids Chemical class 0.000 description 2
- 235000011194 food seasoning agent Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 235000021255 galacto-oligosaccharides Nutrition 0.000 description 2
- 150000003271 galactooligosaccharides Chemical class 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000000665 guar gum Substances 0.000 description 2
- 229960002154 guar gum Drugs 0.000 description 2
- 235000010417 guar gum Nutrition 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 210000004558 lewy body Anatomy 0.000 description 2
- 235000021388 linseed oil Nutrition 0.000 description 2
- 239000000944 linseed oil Substances 0.000 description 2
- 235000020667 long-chain omega-3 fatty acid Nutrition 0.000 description 2
- 238000002595 magnetic resonance imaging Methods 0.000 description 2
- 229940035034 maltodextrin Drugs 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 210000000653 nervous system Anatomy 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 235000019629 palatability Nutrition 0.000 description 2
- 239000001814 pectin Substances 0.000 description 2
- 235000010987 pectin Nutrition 0.000 description 2
- 229920001277 pectin Polymers 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- 238000002600 positron emission tomography Methods 0.000 description 2
- 235000004252 protein component Nutrition 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 235000019627 satiety Nutrition 0.000 description 2
- 230000036186 satiety Effects 0.000 description 2
- 150000004671 saturated fatty acids Chemical class 0.000 description 2
- CXMXRPHRNRROMY-UHFFFAOYSA-N sebacic acid Chemical compound OC(=O)CCCCCCCCC(O)=O CXMXRPHRNRROMY-UHFFFAOYSA-N 0.000 description 2
- TYFQFVWCELRYAO-UHFFFAOYSA-N suberic acid Chemical compound OC(=O)CCCCCCC(O)=O TYFQFVWCELRYAO-UHFFFAOYSA-N 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 230000009529 traumatic brain injury Effects 0.000 description 2
- 230000001228 trophic effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- TWNIBLMWSKIRAT-RWOPYEJCSA-N (1r,2s,3s,4s,5r)-6,8-dioxabicyclo[3.2.1]octane-2,3,4-triol Chemical compound O1[C@@]2([H])OC[C@]1([H])[C@@H](O)[C@H](O)[C@@H]2O TWNIBLMWSKIRAT-RWOPYEJCSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 206010000117 Abnormal behaviour Diseases 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010013654 Drug abuse Diseases 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 229920002488 Hemicellulose Polymers 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000019022 Mood disease Diseases 0.000 description 1
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 229920000305 Nylon 6,10 Polymers 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 241001422033 Thestylus Species 0.000 description 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
- XCCTYIAWTASOJW-UHFFFAOYSA-N UDP-Glc Natural products OC1C(O)C(COP(O)(=O)OP(O)(O)=O)OC1N1C(=O)NC(=O)C=C1 XCCTYIAWTASOJW-UHFFFAOYSA-N 0.000 description 1
- 201000004810 Vascular dementia Diseases 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- 239000005862 Whey Substances 0.000 description 1
- 102000007544 Whey Proteins Human genes 0.000 description 1
- 108010046377 Whey Proteins Proteins 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 206010001584 alcohol abuse Diseases 0.000 description 1
- 208000025746 alcohol use disease Diseases 0.000 description 1
- 230000036626 alertness Effects 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- AEMOLEFTQBMNLQ-BKBMJHBISA-N alpha-D-galacturonic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-BKBMJHBISA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 210000001130 astrocyte Anatomy 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000006931 brain damage Effects 0.000 description 1
- 231100000874 brain damage Toxicity 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000000828 canola oil Substances 0.000 description 1
- 235000019519 canola oil Nutrition 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229940106189 ceramide Drugs 0.000 description 1
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 229940084521 choline 300 mg Drugs 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 235000021323 fish oil Nutrition 0.000 description 1
- VZCCETWTMQHEPK-UHFFFAOYSA-N gamma-Linolensaeure Natural products CCCCCC=CCC=CCC=CCCCCC(O)=O VZCCETWTMQHEPK-UHFFFAOYSA-N 0.000 description 1
- VZCCETWTMQHEPK-QNEBEIHSSA-N gamma-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O VZCCETWTMQHEPK-QNEBEIHSSA-N 0.000 description 1
- 235000020664 gamma-linolenic acid Nutrition 0.000 description 1
- 229960002733 gamolenic acid Drugs 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000005171 mammalian brain Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 230000004898 mitochondrial function Effects 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 235000003715 nutritional status Nutrition 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000003346 palm kernel oil Substances 0.000 description 1
- 235000019865 palm kernel oil Nutrition 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 235000011962 puddings Nutrition 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 238000002603 single-photon emission computed tomography Methods 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 229940083466 soybean lecithin Drugs 0.000 description 1
- 208000020431 spinal cord injury Diseases 0.000 description 1
- 125000005480 straight-chain fatty acid group Chemical group 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 235000019157 thiamine Nutrition 0.000 description 1
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- 239000011721 thiamine Substances 0.000 description 1
- 238000003325 tomography Methods 0.000 description 1
- 229950010342 uridine triphosphate Drugs 0.000 description 1
- PGAVKCOVUIYSFO-UHFFFAOYSA-N uridine-triphosphate Natural products OC1C(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)OC1N1C(=O)NC(=O)C=C1 PGAVKCOVUIYSFO-UHFFFAOYSA-N 0.000 description 1
- 230000036325 urinary excretion Effects 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
- 210000004916 vomit Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 235000020795 whole food diet Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Pediatric Medicine (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
本发明涉及一种脂质成分用于支持脑功能的用途。所述脂质成分中每100g该脂质成分的脂肪酸含有作为中链脂肪酸的至少4g己酸和/或至少5g辛酸、至少1g二十碳五烯酸以及大于0.4gα-亚麻酸。
Description
技术领域
本发明涉及含有所选择的脂肪酸的脂质混合物,及其在制备用于改善哺乳动物特别是年长者的营养产品或药物产品中的用途。
背景技术
神经系统,特别是脑,在哺乳动物的生命中发挥重要作用。例如认知、情绪、社交、感觉、运动和调节等功能主要由脑决定。在西方社会中,越来越多的与脑功能相关的疾病、障碍和问题正在被意识到。例如由于中毒如酒精滥用或药物滥用、由于外伤如由运动事故、工作事故、车辆事故等导致的外伤性脑损伤(TBI),或由于全身营养不良,都会使年轻人遭受脑损伤的情形增多。此外,在衰老过程中,在神经系统尤其是脑中会出现若干有害变化。因此,脑部的机能障碍在年长者、特别是虚弱或营养不良的年长者中尤其是个问题。因此,在该群体中,会经常观察到与神经系统功能失调有关或由其导致的若干疾病和障碍。实例有几种形式的痴呆,例如血管性痴呆、阿耳茨海默病、路易体痴呆(dementiawith Lewy body);杭廷顿舞蹈病、帕金森病;心境障碍,例如多种形式的抑郁,以及其他疾病或障碍例如行为异常,例如在日常生活中,拒绝社会活动和犹豫不决。
许多脂质混合物已被用在制造改善脑功能的食品中。例如WO2006/118665公开了一种通过增加内源性酮的水平来减少蛋白质在哺乳动物脑中聚集的方法。内源性酮的水平的增加可通过给予中链脂肪酸(MCT)和少量的可消化碳水化合物而实现。WO 2007/001883公开了使用MCT和肉毒碱来改善线粒体功能。US 6,835,750公开了以0.5-10g/kg体重每天的剂量使用MCT来治疗阿耳茨海默病。但是,通常已知的是,MCT的高剂量给药可能会导致肠胃不适。此外,MCT给药导致饱腹感,这可能会减少后续的进餐量。这通常是患者或年长者所不希望的。此外MCT的生成酮的特征随时间下降,这使得需要消耗越来越多的MCT来获得相同的生成酮的效果。此外,MCT的消耗可导致例如甘油三酯的血浆水平升高,这是存在心血管障碍或脑血管障碍患病风险的人、例如年长者和肥胖者所不希望的。EP 1282365公开了用含有ω-3长链多不饱和脂肪酸(ω-3LCPUFA)和磷脂的混合物结合特定的维生素B来治疗血管疾病和痴呆的用途。JP 10136937公开了含有用于激活脑细胞功能的二十二碳六烯酸(docosahexanoic acid)、二十碳五烯酸和亚油酸的全营养食品。
除用于支持脑功能外,脂质混合物也被提出用于障碍的治疗。US5,886,037公开了含有55-95重量%MCT、5-25重量%ω-3LCP和0-3重量%其他脂肪酸的脂质混合物用于治疗血脂障碍(dyslipidaemia)的用途。EP 1216041公开了用高含量(35-70en%)的含有25-70重量%MCT且ω-6/ω-3=2-7∶1的脂质混合物来生产用于治疗脓毒病或炎性休克的食品的用途。WO 2003/013276公开了用30-70en%的富含油酸(50-70重量%)和一定量的ω-6脂肪酸及1-10重量%的ω-3脂肪酸的脂质混合物来增加肌细胞中的肌细胞内脂质(intramyocellular lipid)水平的用途,据称这对耐力运动员有益。另一方面,还公开了一种用于减少个体中肌细胞内脂质积聚的混合物,该混合物含有40-65重量%MCT且MUFA=0-30重量%以及含有20-50重量%LC饱和脂肪酸。EP 0175468公开了二十二碳六烯酸、二十碳五烯酸和γ-亚麻酸(一种ω-6脂肪酸)的混合物用于治疗癌症的用途。
因此需要适于在需要支持脑功能的患者肠内使用的营养组合物或药物组合物,其不具有现有技术组合物的缺点,所述组合物经证明具有快速效应,并且便于使用且适口。
现本发明者已发现,以特定产品制剂并任选地与蛋白质成分和/或其他组分相结合的形式使用脂质成分,在支持特别是年长者脑功能方面能提供优于现有技术方案的优点。
发明内容
本发明涉及一种用于支持脑功能、治疗神经障碍或疾病例如阿耳茨海默病和治疗认知功能下降的脂质成分,其中所述脂质成分含有一种或多种己酸和/或辛酸源、二十碳五烯酸源和每100g脂质成分的脂肪酸大于0.4g的α-亚麻酸。
所述脂质成分可用于生产营养产品或药物产品。所述产品适于肠内给药于需要支持他或她的脑功能的患者。优选地,所述产品含有一些抗原,例如蛋白质或肽等,这使得所述产品不适于肠胃外给药。因此,本发明涉及一种含有本发明脂质成分的营养产品或药物产品。所述产品可用作增补剂,并可具有液态、半液态或固态形式。
所称的液态形式的产品可以制造成具有较低粘度,这使得它们适于通过导管给药于患者。因此,所述液态形式产品的粘度较低,优选小于40,更优选6-30mPa.s,在20℃、100sec-1的剪切速率下测得。因此,本发明特别涉及含有本发明脂质成分的组合物的用途,其中所述粘度小于40mPa.s,更优选为6-30mPa.s,在20℃、100sec-1的剪切速率下测得。
优选地,所述液态产品含有蛋白质成分、脂质成分和碳水化合物成分,以及维生素类和矿物类或微量元素,以便为不同营养状况的患者的脑功能提供全面的支持。重要的是,尽管包括所有这些成分,但是,产品的渗透值仍低于500、更优选200-470mOsm每千克产品,以便增加顺应性和增加对脑的支持,尤其是对老年患者。通过该措施防止肠胃不适。这些摩尔渗透浓度值也可适用于pH在3.8和7之间并且经调味的产品。所述调味性能对获得优良的产品适口性和极好的对推荐的给药方式的长期顺应性来说是重要的。因此,本发明特别涉及含有本发明脂质成分的组合物的用途,其中渗透值小于500mOsm,更优选在200和470mOsm每kg产品之间。
脂质水平大于45en%、优选大于55en%、最优选大于60en%、最多达例如75en%的即用型产品比常规产品将优选具有更高的干质量含量每单位剂量。当所述产品的干质量含量为大于32g/100g、优选35-96g/100g、更优选40-95g/100g、尤其是45-80g/100g即用型产品时,可获得对处方方案的良好顺应性。实例为本领域中已知的冰淇淋、布丁和棒剂(bar)。
所述产品,特别是液态产品的能量密度为大于0.9kcal/ml、优选1-7kcal/ml(4.2-29.4kJ/ml),并且最优选2.4-6.5kcal/ml(10.1-27.3kJ/ml)。因此,本发明还涉及含有本发明脂质成分、能量密度大于0.9kcal/ml、优选1-7kcal/ml(4.2-29.4kJ/ml)并且最优选2.4-6.5kcal/ml(10.1-27.3kJ/ml)的组合物的用途。
已开发出完全支持脑功能的下文详细描述的脂质成分。神经元细胞(特别是神经元)、星形细胞和胶质细胞的营养状况相对于现有技术的脂质混合物得到改善。所述状况例如可通过测量脑细胞的萎缩或测定脑的生物化学性质或生理性质来进行监测,测量脑细胞的萎缩例如通过使用本领域中所知的MRI(磁共振成像)方法进行,测定脑的生物化学性质或生理性质例如通过使用PET(正电子发射断层摄影术)、脑脊液成分分析或单光子发射计算机断层摄影术(SPECT)进行。
基于脂质成分中脂肪酸的总量计,所述脂质成分含有至少0.4、优选1-12重量百分比(重量%)的α-亚麻酸(aLA)和优选至少0.4、优选1-20重量%的二十碳五烯酸(EPA)。增加aLA的适宜来源包括低芥酸菜籽油和亚麻油。
所述脂质成分优选含有二十二碳六烯酸(DHA)的量为所述成分中脂肪酸总量的至少0.5、优选1-35、更优选5-30重量%,并且其中DHA对EPA的重量比优选在0.2-7、更优选0.8-4的范围内。脂质混合物中包含的DHA的量将改善脑细胞的营养状况。
所述脂质成分中每100g全部脂肪酸含有优选大于15g的DHA、优选大于3g的EPA和优选大于1g的亚麻酸,和优选大于3g、优选4-20g的己酸,及优选大于4g、优选5-20g的辛酸。以所述量包含所有这些脂肪酸不仅改善了脑细胞的营养状况,而且还可影响脑细胞的其他性能,从而使得可观察到对脑功能的有效(net)支持。
在脂质成分中,α-亚麻酸的重量优选为亚油酸重量的0.3-1倍。本发明者认为,相对较高的α-亚麻酸相对于亚油酸的量不是由于对脑细胞的直接作用,而是间接作用,尽管观察到该作用的早期表现。
产品中所述脂质成分优选含有10-60、更优选25-45、最优选28-40g中链甘油三酯(MCT)每100g脂质成分(或相同量的中链脂肪酸,基于100g全部脂肪酸计)。根据产品的剂量方案,得到的剂量为小于0.5g MCT每千克体重每天,从而防止肠胃不适。
所述中链脂肪酸(MCT)定义为具有6、7、8、9或10个碳原子的直链或支链的饱和羧酸。支持脑功能的最好结果用具有6、7或8个碳原子的直链脂肪酸得到,并且这些脂肪酸的总重量与9和10个碳原子的脂肪酸的总重量相比应优选大于2.5。
中链脂肪酸的最好来源为MCT或富含来自椰子油、奶脂质类或奶油、棕榈仁油或棕榈油的中链脂肪酸的所选成分。所述来源提供具有较高己酸(C6:0)和辛酸(C8:0)含量的甘油三酯,并且还可含有C10:0或其他脂肪酸。重要的是,满足C6:0和C8:0的剂量,对于脂质混合物的其他要求也应满足。这使得可使用具有较低C10:0水平的MCT源。特别地,这类MCT含有小于20重量%的C 10:0,优选小于15重量%,基于MCT油中的脂肪酸计。C10脂肪酸的总量优选小于组合物中全部脂肪酸的10重量%,更优选小于7重量%。
此外,使用至少一种如下的己酸和/或辛酸源时也可获得较好的结果:基于该源中脂肪酸总量计,该源可提供45-100重量%的己酸和/或辛酸,并且其中该源不是中链甘油三酯油(MCT)。所述源包括含有一种或两种碳数为6-10的饱和脂肪酸的甘油二酯或甘油单酯。所述成分的使用可增加适口性和减少在摄入40g脂质丸剂后的肠胃不适性。因此,本发明还涉及含有甘油二酯或甘油单酯源的脂质成分用于改善脑功能的用途,所述源提供基于脂肪酸总量计45-100重量%的己酸和/或辛酸。
所述脂质成分优选含有至少6重量%的磷脂或溶血磷脂。这会减少富含含有己酸和辛酸的甘油三酯的产品产生的肠胃不适的风险。其还有利于微量元素和维生素的生物利用率。
使用阿氏热量系数可得,所述脂质成分在给药至人体后优选贡献产品能量的大于45%、更优选48-70%,所述阿氏热量系数为:可消化的碳水化合物(4kcal/g)、蛋白质(4kcal/g)和脂质(9kcal/g),对产品中的有机酸和营养纤维、矿物和维生素为0。尽管所述产品含有相对较高量的脂质、特别是MCT,但是其给药不会导致如通常在现有技术中的高脂肪产品中所观测到的消极副作用。所述副作用包括强饱腹感、肠胃不适性,例如呕吐和腹泻,还包括对产品中其他组分例如维生素、微量元素的可利用率的影响,以及蛋白质和碳水化合物的消化速率的下降。这些优点被认为归因于对脂质混合物本身的选择,以及对产品中其他组分的性质的选择。
所述脂质成分含有优选大于10重量%的MCT和优选0.1-40重量%、更优选1-32重量%、尤其是2-20重量%的ω-3LCP(ω-3LCP被定义为具有至少两个不饱和碳-碳键和至少20个碳原子的ω-3脂肪酸)。
脂质混合物中游离脂肪酸的量优选小于2重量%、更优选小于1重量%,以便使肠胃不适感最小化。
所述脂质成分定义为即用型产品的一部分,该产品通过用一种适宜的溶剂使用该特定产品可接受的方法对该产品进行提取而得到,如1995年出版的AOAC(American Organisation of Analytical Chemists)手册中所公开。因此脂质成分还含有磷脂、糖脂、神经酰胺、甘油单酯、甘油二酯和甘油三酯等。
所述脂质成分优选与核苷酸成分组合用于支持脑功能的产品中。当核苷酸成分含有尿苷或胞苷源时,可获得最好的药效结果和较低的不利副作用。
尿苷源优选选自尿嘧啶,尿苷,尿苷的磷酸酯形式例如尿苷单磷酸酯、尿苷二磷酸酯或尿苷三磷酸酯,它们的盐以及尿苷的酯,或者为含有单体或多聚体形式羧酸的磷酸酯。特别地,其中尿苷已被乙酸、正己酸、辛酸、或正癸酸酰化的那些尿苷衍生物是有效的,因为所述衍生物会增加尿苷源的生物利用率。使这些中链脂肪酸与尿苷反应,例如在尿苷的5′位上反应的方法对其他脂肪酸而言在本领域中也是已知的,包括常规的酰化方法。
本发明还涉及含有0.05-100重量%、尤其0.2-10重量%的所述尿苷C6-C10酰化物、余量物为食品或食品级组分的组合物,该组合物尤其可含有1-75重量%的脂质成分。本发明还涉及尿苷C6-C10酰化物与脂质组合物的重量比在1∶200和1∶1之间,尤其在1∶60和1∶3之间的混合物。
必须给予的剂量以UMP给出。其他尿嘧啶源的量可通过采用相应于UMP量的摩尔当量进行计算。
类似地,胞苷源优选选自胞苷、其磷酸酯、其盐和胞苷的酯。也同尿嘧啶类似,多个胞苷形式之间的剂量可相互进行比较和换算。
为获得对脑功能的更好的改善,计算成尿嘧啶当量的尿苷和计算成胞嘧啶的胞苷的重量的总和为腺嘌呤、鸟嘌呤、胸腺嘧啶、肌苷或其他核酸碱基(nucleobase)的至少2倍,优选至少4倍。
当剂量UMP或CMP为每100ml即用产品至少40mg、优选50-6000、更优选60-1000mg时,可得到最好的药效和最小的不利副作用。最优选每100g即用产品含有70-600mg UMP。每100g脂质成分中待使用的最大量优选为100mg、更优选200mg-20g、最优选400mg-10g每100g脂质。
优选所述产品含有纤维成分,该纤维成分含有食品级营养纤维。更优选所述纤维含有大于10重量%、尤其大于20重量%的链长为3-20个糖单元的低聚不消化物质。特别地,当所述纤维混合物含有(例如至少10重量%)阿拉伯聚糖、甘露聚糖、糖醛酸(例如聚半乳糖醛酸(galacturonan))等低聚糖或半乳聚糖或其混合物时,可观察到所述益处。在一个具体的实施方案中,所述纤维含有至少20重量%、尤其至少30重量%的分子量在500-10.800(=DP 3-60)范围内的寡糖和多糖。当所述纤维成分含有寡糖(3-20个单元)和链长大于60个糖单元的聚合纤维及可能的中等长度(20-60个单元)的聚合纤维的混合物时可获得甚至更好的结果。所述聚合纤维包括纤维素和半纤维素类型的纤维,如豌豆和大豆中的那些聚合纤维。
适宜的寡糖为合成寡糖,例如半乳寡聚糖,或水解的天然纤维,如水解的瓜耳胶或水解的甜菜纤维或水解的果胶,或其混合物。为得到最好的结果,产品中纤维的重量应该为该产品中脂质重量的0.04-2、优选0.07-1、更优选0.1-0.8倍。当富含MCT的制剂中含有纤维混合物时,可显著改善肠胃不适感和食后的脂质分布。
有利地含有的其他组分为本领域已知的肉毒碱、维生素、微量元素、矿物。产品中优选包含叶酸、维生素B 12和维生素B6中的至少一种并且更优选地包含所有这三种。每100ml即用型产品应包含的叶酸的量为50-500μg,维生素B6的量为0.5-5mg,并且维生素B12的量为0.8-100μg,或者日常剂量单位表示的相同量。关于脂质成分,所述量优选为每100g脂质0.5-10mg叶酸,和/或5-100mg维生素B6,和/或8-2000μg维生素B12。
适宜的肉毒碱源包括本领域已知的L-肉毒碱或酰基肉毒碱,例如乙酰基、丁酰基、异丁酰基或丙酰基肉毒碱。适宜剂量为2-100、优选10-80mg每100ml即用型产品或每日剂量单位。
所述产品还可含有蛋白质物质和可消化的碳水化合物。可消化碳水化合物的量优选小于总能量含量的50%、更优选5-45%、最优选10-40%。
所述产品可以每天50-400ml,尤其是75-200ml,最优选100-150ml的量使用,基于即用型液体计。每天使用的脂质成分的量可在1-100g,尤其是2.5-50g,最优选4-20g脂质成分每天或每日剂量单元的范围内。
所述产品可用于改善或支持需要脑功能支持的人的脑功能,可以是任意年龄的人,例如婴儿、儿童、青少年、青年人、成年人和老年人。尤其可预见的是支持有中枢神经系统受损风险或正遭受中枢神经系统损害的人的脑功能,所述中枢神经系统损害例如由车辆事故、运动事故、工作事故、战斗情形等引起的例如脑外伤或脊髓损伤。特别可预见的是老年人,更特别的是虚弱的老年人或不肥胖的老年人。所述产品可对apoE4阳性或阴性的人有效。
同含有常规脂质混合物的现有技术的产品相比,所述产品具有在其消耗后能降低甘油三酯和二羧酸的血浆水平的其他优点。此外,二羧酸例如己二酸、辛二酸和癸二酸的尿排泄量减少,这更符合生理性并支持酮体被消费者更好的利用。未观察到例如肠胃不适感或对脑容量或脑生长的消极影响等副作用。同产品中含有类似脂质浓度的现有技术的制剂相比,所述产品极为适口并表现出对矿物和维生素产生更好的利用率。这些优点归因于与现有技术制剂的一种或多种差异。
包含己酸(C6:0)和/或辛酸(C8:0)使得含有较低量的DHA即可具有与具有不含己酸和/或辛酸的脂质混合物的产品的DHA剂量较高时相同的效果。在含有DHA的脂质混合物中包含中链脂肪酸也使得包含较低量的中链甘油三酯脂肪酸即可观察到与不含具有DHA的脂质混合物的中链甘油三酯的剂量较高时相同的效果。
支持脑功能意指改善与日常生活活动、认知力、社交技能、决策技能、运动技能和无需他人帮助而生活的能力有关的技能。所述改善可通过测定人实施所述技能的能力进行量度。日常生活活动包括工具性活动、操作活动和基本活动。这些活动包括使用家用器具、协调运动、做出快速运动、行走、洗衣、洗餐具、打扫卫生、旅行等的能力。
也应支持神经障碍的前驱性患者,遭受认知力衰减的患者,或遭受老年痴呆、阿耳茨海默病、糖尿病或胰岛素耐受性患者,或经历过物理创伤或毒理创伤的患者的脑功能。
本发明产品显示具有快速药效。如果现有技术的制剂显示药效,则它们在使用至少几周后才显示出来。本发明制剂可在开始使用该制剂后几小时或几天内显示药效。
以科学上合理的并且可靠的方法来测量上述技能的标准化方案为本领域已知。
实施例
实施例1
用于前驱性患者的液体
每100ml所述液体含有3g蛋白质(酪蛋白/乳清为80/20)、7g脂质(MCT/芸苔/磷脂/海产油(marine oil)的重量比为50/30/6/14)和8g可消化的碳水化合物(麦芽糖糊精19/果糖/乳糖的比例为60/10/30)以及:
UMP 500mg[其他核苷酸<10mg];胆碱300mg;
维生素B61.1mg;维生素B122.3μg;叶酸300μg;现有技术中用作增补剂的其他微量元素、矿物和维生素;
半乳寡聚糖0.6g;豌豆纤维0.6g
得到490mOsm/kg水的摩尔渗透浓度。
在一周内以125ml/天的量将饮剂给予先驱性痴呆患者,以便查看对脑功能、特别是对更好的社交技能、更多的活动和适合度及更好的认知功能、及更好的机警性和集中注意力的能力的效果。
实施例2
每天一次或两次用于患阿耳茨海默病的患者的棒剂。
每25g干质量的所述棒剂含有:
10.5g脂质:(40MCT;乳脂25,鱼油15,芸苔15,巧克力5)
3g蛋白质(乳蛋白质)
9g碳水化合物(葡萄糖浆)
1g预混合物,其提供100ug叶酸,2ug维生素B 12和1mg维生素B6及200mg UMP
1.5g纤维(GOS 10,水解的瓜耳胶40,大豆纤维50)
实施例3
用于认知力下降的患者的液体。
患者应该每天至少消耗200ml所述产品,每100ml所述产品含有:
能量600kcal
蛋白质3.1g乳蛋白质
脂质14.6g;7g C6:0+C8:0;0.2gα-亚麻酸;0.6g二十碳五烯酸和
0.9g二十二碳六烯酸,5.9g其他脂肪酸
碳水化合物0.6g
UMP 500mg
纤维:1.5g 1∶1的甜菜纤维和经水解的果胶的混合物
维生素A 253IU;维生素D 2.2IU;维生素C 9mg;维生素K 6μg;硫胺素0.14mg;核黄素0.15mg;烟酸1.5mg;维生素B61.1mg;叶酸100μg;维生素B120.9μg;生物素4μg;泛酸0.6mg;肌醇4mg;Na 4.3mg;K 4.1mg;Cl 4.3mg;Ca 86mg;P 100mg;Mg 22mg;Zn 1.2mg;Fe 1.5mg;Cu 0.12mg;Mn 0.13mg;碘化物18μg;Mo 6μg;Se 4.4μg;Cr 3μg
实施例4.
支持年长者脑功能的液体饮剂,每100ml该饮剂含有:
能量630kJ
蛋白质6.0g酪蛋白
脂质8.7g,其含有50重量%MCT油、15%海产油和35重量%植物油的混合物
碳水化合物12g(80麦芽糖糊精,20葡萄糖浆)
膳食纤维1.2g,为实施例3的混合物
UMP 400mg
现有技术用作增补剂的其他微量元素、矿物和维生素
实施例5
适用于遭受物理性脑创伤的棒剂,每50g该棒剂含有:
12g脂质成分(7.2g甘油二酯,其中每100g脂肪酸含有总量80g的己酸和辛酸,2.4g亚麻籽油、1.2g海产油、1.2g大豆卵磷脂),
21g可消化碳水化合物(麦芽糖糊精、甘油)
11g脱脂奶粉
1.3g灰分
4.7g水
Claims (17)
1.用于支持脑功能的脂质成分,所述脂质成分含有己酸和/或辛酸、二十碳五烯酸和大于0.4gα-亚麻酸每100g该脂质成分的脂肪酸。
2.权利要求1的脂质成分,其中所述脂质成分基于该成分中脂肪酸的总和计含有至少1重量百分比(重量%)的α-亚麻酸和至少1重量%的二十碳五烯酸。
3.权利要求1或2的脂质成分,其中所述脂质成分含有其量为所述脂质成分中脂肪酸总和的至少10重量%的二十二碳六烯酸(DHA),并且其中DHA对EPA的重量比为0.2-7。
4.前述权利要求中任一项的脂质成分,其中所述脂质成分每100g脂肪酸含有大于15g的DHA、大于3g的EPA、大于1g的α-亚麻酸、大于4g的己酸和大于的5g辛酸。
5.前述权利要求中任一项的脂质成分,其中所述脂质成分中α-亚麻酸的重量为亚油酸重量的0.3-1倍。
6.前述权利要求中任一项的脂质成分,其中使用至少一种己酸和/或辛酸源,所述源基于该源中脂肪酸的总量计提供45-100重量%的上述脂肪酸,并且其中该源不为中链甘油三酯油。
7.前述权利要求中任一项的脂质成分,其中所述脂质成分含有10-60g中链甘油三酯每100g该脂质成分。
8.前述权利要求中任一项的脂质成分,其中所述脂质成分含有至少6重量%的磷脂或溶血磷脂。
9.前述权利要求中任一项的脂质成分,其中所述脂质成分在给药至人体后贡献产品能量的45-70%。
10.前述权利要求中任一项的脂质成分,其中所述脂质成分含有10-60重量%的MCT和1-30重量%的ω-3LCP。
11.前述权利要求中任一项的脂质成分,其中所述脂质成分与一种核苷酸成分组合,并且其中所述核苷酸成分包括尿苷源或胞苷源。
12.权利要求11的脂质成分,其中所述尿苷源选自尿嘧啶、尿苷、尿苷的磷酸酯形式、尿苷与羧酸的酯,所述胞苷源选自胞苷、其磷酸酯、胞苷的酯,并且其中计算成尿嘧啶当量的尿苷的重量和计算成胞嘧啶的胞苷的重量的总和为腺嘌呤、鸟嘌呤、胸腺嘧啶、肌苷或其他核酸碱基的重量的至少2倍,优选至少4倍。
13.前述权利要求中任一项的脂质成分,其中所述产品含有包含一种低聚糖的纤维成分。
14.前述权利要求中任一项的脂质成分,其中所述产品的干质量含量为大于32、优选35-90、更优选40-88g每100g即用型产品。
15.前述权利要求中任一项的脂质成分,其中所述脑功能与日常生活活动、认知力、社交技能、决策技能、运动技能和无需他人帮助而生活的能力有关。
16.前述权利要求中任一项的脂质成分,其中支持神经障碍的前驱性患者,或患老年痴呆、阿耳茨海默病、糖尿病或胰岛素耐受性或经历过物理创伤或毒理创伤的患者的脑功能。
17.用于改善脑功能的含有甘油二酯和甘油单酯源的脂质成分,所述源提供45-100重量%的己酸和/或辛酸。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/NL2007/050306 WO2009002145A1 (en) | 2007-06-26 | 2007-06-26 | Lipid composition for improving function of brain functioning |
NLPCT/NL2007/050306 | 2007-06-26 | ||
PCT/NL2008/050410 WO2009002165A1 (en) | 2007-06-26 | 2008-06-20 | Lipid composition for improving brain function |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101742926A true CN101742926A (zh) | 2010-06-16 |
CN101742926B CN101742926B (zh) | 2017-06-09 |
Family
ID=38457798
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN200880024527.0A Active CN101742926B (zh) | 2007-06-26 | 2008-06-20 | 用于改善脑功能的脂质组合物 |
Country Status (11)
Country | Link |
---|---|
US (2) | US8283335B2 (zh) |
EP (2) | EP2162019B1 (zh) |
CN (1) | CN101742926B (zh) |
AT (1) | ATE538665T1 (zh) |
BR (1) | BRPI0813320B1 (zh) |
DK (1) | DK2436275T3 (zh) |
ES (2) | ES2432345T3 (zh) |
PL (2) | PL2162019T3 (zh) |
PT (2) | PT2436275E (zh) |
WO (2) | WO2009002145A1 (zh) |
ZA (1) | ZA200909230B (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104305192A (zh) * | 2014-10-23 | 2015-01-28 | 贡岳松 | 改善老年痴呆症患者记忆的功能性食品及其制备方法 |
CN108712866A (zh) * | 2016-02-29 | 2018-10-26 | 朴启彰 | 健脑食品或健脑饮品与其施用方法 |
CN108777997A (zh) * | 2016-03-30 | 2018-11-09 | 雀巢产品技术援助有限公司 | 营养组合物及其用途 |
Families Citing this family (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009002166A1 (en) * | 2007-06-26 | 2008-12-31 | N.V. Nutricia | Improving memory in subjects with mini-mental state examination of 24-26 |
WO2009002145A1 (en) | 2007-06-26 | 2008-12-31 | N.V. Nutricia | Lipid composition for improving function of brain functioning |
WO2009002146A1 (en) | 2007-06-26 | 2008-12-31 | N.V. Nutricia | Supporting activities of daily living |
WO2009002148A1 (en) | 2007-06-27 | 2008-12-31 | N.V. Nutricia | Food composition for prodromal dementia patients |
CN101820754A (zh) † | 2007-10-04 | 2010-09-01 | 雀巢产品技术援助有限公司 | 用于增强认知功能的组合物与方法 |
PL2222311T3 (pl) | 2007-12-20 | 2013-08-30 | Nutricia Nv | Ciekły produkt zawierający nukleotydy/nukleozydy |
SG188107A1 (en) * | 2008-02-01 | 2013-03-28 | Research In Motion Ltd | System and method for uplink timing synchronization in conjunction with discontinuous reception |
WO2010088700A1 (en) * | 2009-02-02 | 2010-08-05 | Martek Biosciences Corporation | Methods for improving cognitive function and decreasing heart rate |
EP2258216A1 (en) * | 2009-06-02 | 2010-12-08 | Nestec S.A. | Nutritional Composition for Supporting Brain Development and Function of Toddlers |
EP2258218A1 (en) * | 2009-06-02 | 2010-12-08 | Nestec S.A. | Nutritional Composition for Supporting Brain Development and Function of Toddlers |
EP2258217A1 (en) * | 2009-06-02 | 2010-12-08 | Nestec S.A. | Nutritional Composition for Supporting Brain Development and Function of Children |
CN102884201B (zh) | 2010-01-19 | 2016-04-13 | 帝斯曼知识产权资产管理有限公司 | 生产二十碳五烯酸的微生物、脂肪酸组成物及其制作方法与用途 |
SG10201707519PA (en) * | 2010-12-31 | 2017-10-30 | Abbott Lab | Neutral human milk oligosaccharides to promote growth of beneficial bacteria |
WO2012125020A1 (en) | 2011-03-14 | 2012-09-20 | N.V. Nutricia | Method for treating neurotrauma |
CN108771240A (zh) * | 2011-07-21 | 2018-11-09 | 帝斯曼知识产权资产管理有限公司 | 脂肪酸组合物 |
WO2013066152A1 (en) * | 2011-10-31 | 2013-05-10 | N.V. Nutricia | Method for improving executive function |
WO2013066151A1 (en) | 2011-10-31 | 2013-05-10 | N.V. Nutricia | Improving recognition |
BR112014020177A8 (pt) * | 2012-03-02 | 2021-10-19 | Nutricia Nv | Uso de uma composição para a fabricação de um produto para diminuir, prevenir ou reverter a conectividade cerebral funcional prejudicada e/ou organização da rede cerebral prejudicada |
WO2013129914A1 (en) | 2012-03-02 | 2013-09-06 | N.V. Nutricia | Method for improving functional synaptic connectivity |
US20140256813A1 (en) * | 2013-03-08 | 2014-09-11 | Nordic Naturals, Inc. | Methods for the treatment of brain injury using omega-3 fatty acids |
WO2014171813A1 (en) | 2013-04-17 | 2014-10-23 | N.V. Nutricia | Nutritional composition for improving brain function in phenylketonuria |
CN105517452A (zh) * | 2013-08-01 | 2016-04-20 | 荷兰洛德斯克罗科兰有限公司 | 甘油酯组合物 |
WO2015034984A1 (en) * | 2013-09-05 | 2015-03-12 | Emory University | Nutritional formulas comprising medium chain fatty acids or esters thereof and methods related thereto |
US9216199B2 (en) | 2013-12-05 | 2015-12-22 | Buriva, LLC | Nutritional supplement containing phospholipid-DHA derived from eggs |
US9549937B2 (en) | 2013-12-05 | 2017-01-24 | Burvia, LLC. | Composition containing phospholipid-DHA and folate |
US9610302B2 (en) | 2013-12-05 | 2017-04-04 | Buriva, LLC. | Composition containing phospholipid-DHA and B vitamins |
US9233114B2 (en) | 2013-12-05 | 2016-01-12 | Buriva, LLC | Dietary supplement containing phospholipid-DHA derived from eggs |
WO2015084158A1 (en) * | 2013-12-06 | 2015-06-11 | N.V. Nutricia | A pyrimidine derivative and a fatty acid source for use in the treatment of constipation |
WO2015115885A1 (en) | 2014-01-31 | 2015-08-06 | N.V. Nutricia | Method for reducing white matter lesions, white matter hyperintensities (wmh), leukoaraiosis or periventricular white matter disease in elderly |
WO2016010102A1 (ja) * | 2014-07-17 | 2016-01-21 | 日清オイリオグループ株式会社 | 栄養組成物 |
TWI722992B (zh) * | 2014-07-23 | 2021-04-01 | 一般財團法人糧食研究會 | 腦功能改善劑、及認知功能障礙的預防或治療劑 |
WO2016053085A1 (en) * | 2014-09-30 | 2016-04-07 | N.V. Nutricia | Composition comprising a uridine source and butyrate producing fibres for preventing gastrointestinal disorders |
WO2016148561A1 (en) | 2015-03-16 | 2016-09-22 | N.V. Nutricia | Method for improving bladder function |
CA2908184C (en) | 2015-10-13 | 2019-10-22 | Roto-gro Inc. | Stackable modular rotatable gardening system |
WO2017069613A1 (en) | 2015-10-23 | 2017-04-27 | N.V. Nutricia | Method for improving recognition and/or working memory in hyperphenylalanimenia and phenylketonuria patients |
WO2017093060A1 (en) * | 2015-12-04 | 2017-06-08 | Nestec S.A. | Method for improving cognition |
WO2017155387A1 (en) | 2016-03-08 | 2017-09-14 | N.V. Nutricia | Method for supporting memory function and/or cognitive function |
WO2017183956A1 (en) * | 2016-04-18 | 2017-10-26 | N.V. Nutricia | Linoleic acid and alpha-linolenic acid for use for reducing early-life stress induced cognitive decline |
EP3445353A1 (en) * | 2016-04-18 | 2019-02-27 | N.V. Nutricia | Linoleic acid and alpha-li nolenic acid for use for reducing early-life stress induced cognitive decline/reduction in neurogenesis |
US20180085331A1 (en) * | 2016-09-26 | 2018-03-29 | Garrett E. Wdowin | Compositions for mitigating head trauma |
US10456368B2 (en) | 2016-09-26 | 2019-10-29 | Garrett E. Wdowin | Compositions for mitigating brain trauma and methods thereof |
PL3600364T3 (pl) | 2017-06-14 | 2021-01-11 | 4D Pharma Research Limited | Kompozycje zawierające szczep bakteryjny z rodzaju megasphaera i ich zastosowania |
US20210267251A1 (en) * | 2018-06-21 | 2021-09-02 | Societe Des Produits Nestle S.A. | Compositions and methods using a nicotinamide adenine dinucleotide (nad+) precursor and at least one ketone or ketone precursor |
WO2020014051A1 (en) * | 2018-07-09 | 2020-01-16 | Wdowin Garrett E | Compositions for mitigating brain trauma and methods thereof |
AU2022345465A1 (en) | 2021-09-17 | 2024-03-21 | N.V. Nutricia | Solid composition suitable as a nutritional composition or supplement for animals that suffer from brain related disorders, decline or diseases |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH06237734A (ja) * | 1991-11-06 | 1994-08-30 | Sanwa Kagaku Kenkyusho Co Ltd | 機能後退性疾患用食品組成物 |
US6835750B1 (en) * | 2000-05-01 | 2004-12-28 | Accera, Inc. | Use of medium chain triglycerides for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism II |
WO2007000529A2 (fr) * | 2005-05-16 | 2007-01-04 | Laboratoires Inneov | Traitement de la secheresse keratinique par des glycerides |
Family Cites Families (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3600197A (en) | 1968-08-27 | 1971-08-17 | Merck & Co Inc | Flavor enhancing compositions for foods and beverages |
EP0175468A3 (en) * | 1984-08-10 | 1987-07-22 | Sentrachem Limited | Eicosanoids for use in cancer therapy |
JP2525624B2 (ja) * | 1987-09-21 | 1996-08-21 | 雪印乳業株式会社 | 多価不飽和脂肪酸配合育児用粉乳 |
US5378488A (en) | 1993-06-10 | 1995-01-03 | Abbott Laboratories | Aseptic processing of infant formula |
JP3576318B2 (ja) | 1996-06-19 | 2004-10-13 | 明治乳業株式会社 | 核酸関連物質含有栄養組成物 |
JPH10136937A (ja) * | 1996-11-08 | 1998-05-26 | Takashi Morita | 脳細胞機能向上、血管細胞強化、身体各細胞機能向上栄養総合食品 |
DE69622722T2 (de) | 1996-11-20 | 2003-02-27 | Nutricia Nv | Fette enthaltende Ernährungszusammensetzung zur Behandlung des Stoffwechselsyndroms |
EP0891719A1 (en) | 1997-07-14 | 1999-01-20 | N.V. Nutricia | Nutritional composition containing methionine |
JP3731983B2 (ja) * | 1997-08-27 | 2006-01-05 | 明治製菓株式会社 | 痴呆犬の夜鳴き改善薬 |
US8518882B2 (en) | 1998-07-31 | 2013-08-27 | Massachusetts Institute Of Technology | Methods and compositions for ameliorating or inhibiting decline in memory or intelligence or improving same |
US20070004670A1 (en) | 1998-07-31 | 2007-01-04 | Richard Wurtman | Compositions containing citicoline, and methods of use thereof |
FR2787799B1 (fr) | 1998-12-23 | 2001-03-09 | Rhodia Chimie Sa | Composition comprenant une ecorce inorganique et un noyau comportant au moins un compose polyhydroxyle |
EP1090636A1 (en) | 1999-09-13 | 2001-04-11 | Société des Produits Nestlé S.A. | High lipid diet |
GB9925709D0 (en) | 1999-10-30 | 1999-12-29 | Smithkline Beecham Plc | Composition |
DE60138019D1 (de) | 2000-05-01 | 2009-04-30 | Accera Inc | Verwendung von triglyceriden mit mittellangen ketten zur behandlung und vorbeugung der alzheimerschen erkrankung |
US7226916B1 (en) | 2000-05-08 | 2007-06-05 | N.V. Nutricia | Preparation for the prevention and/or treatment of vascular disorders |
HUP0400732A3 (en) | 2001-04-30 | 2007-05-29 | Trommsdorff Arzneimittel | Pharmaceutically active uridine esters |
US6942874B2 (en) | 2001-05-25 | 2005-09-13 | Linguagen Corp. | Nucleotide compounds that block the bitter taste of oral compositions |
EP1285590A1 (en) | 2001-08-08 | 2003-02-26 | Société des Produits Nestlé S.A. | Lipid blends |
NL1019368C2 (nl) | 2001-11-14 | 2003-05-20 | Nutricia Nv | Preparaat voor het verbeteren van receptorwerking. |
US20030114415A1 (en) | 2001-12-14 | 2003-06-19 | Wurtman Richard J. | Compositions and methods for treating and preventing memory impairment using citicoline |
US20040001817A1 (en) | 2002-05-14 | 2004-01-01 | Giampapa Vincent C. | Anti-aging nutritional supplement |
EP2123282A3 (en) | 2003-10-24 | 2010-01-20 | N.V. Nutricia | Immunemodulating oligosaccharides |
US7090879B2 (en) | 2004-03-18 | 2006-08-15 | Abbott Laboratories | Nutritional formula containing select carotenoid combinations |
US9572830B2 (en) | 2004-05-13 | 2017-02-21 | Massachusetts Institute Of Technology | Uridine effects on dopamine release |
CA2579851C (en) | 2004-09-15 | 2018-09-04 | Massachusetts Institute Of Technology | Use of uridine for improving cognitive and neurological functions |
EP1656839A1 (en) | 2004-11-11 | 2006-05-17 | N.V. Nutricia | Nutrition containing lipid blend |
US20060252775A1 (en) | 2005-05-03 | 2006-11-09 | Henderson Samuel T | Methods for reducing levels of disease associated proteins |
PL1888081T3 (pl) | 2005-05-23 | 2017-07-31 | Massachusetts Institute Of Technology | Kompozycje zawierające PUFA i sposoby ich zastosowania |
EP2468273A3 (en) | 2005-06-20 | 2012-07-11 | Accera, Inc. | Method to reduce oxidative damage and improve mitochondrial efficiency |
JP5967855B2 (ja) | 2005-06-30 | 2016-08-10 | サントリーホールディングス株式会社 | 日中活動量の低下および/又はうつ症状の改善作用を有する組成物 |
JP5697293B2 (ja) | 2005-06-30 | 2015-04-08 | サントリーホールディングス株式会社 | 器質的脳障害に起因する高次脳機能の低下に対する改善作用を有する組成物 |
KR20130101596A (ko) | 2005-07-08 | 2013-09-13 | 마텍 바이오싸이언스스 코포레이션 | 치매 및 치매-전단계와 관련된 용태의 치료를 위한 다중불포화 지방산 |
WO2007058523A1 (en) | 2005-11-17 | 2007-05-24 | N.V. Nutricia | Composition with docosapentaenoic acid |
US20070140992A1 (en) | 2005-12-21 | 2007-06-21 | Lynn Schick | Taste masking of essential oils using a hydrocolloid |
ATE509624T1 (de) | 2005-12-23 | 2011-06-15 | Nutricia Nv | Zusammensetzung enthaltend mehrfach ungesättigte fettsäuren, proteine, mangan und/oder molybden und nukleotide/nukleoside, zur behandlung von demenz |
WO2009002166A1 (en) | 2007-06-26 | 2008-12-31 | N.V. Nutricia | Improving memory in subjects with mini-mental state examination of 24-26 |
WO2009002148A1 (en) | 2007-06-27 | 2008-12-31 | N.V. Nutricia | Food composition for prodromal dementia patients |
WO2009002146A1 (en) | 2007-06-26 | 2008-12-31 | N.V. Nutricia | Supporting activities of daily living |
WO2009002145A1 (en) | 2007-06-26 | 2008-12-31 | N.V. Nutricia | Lipid composition for improving function of brain functioning |
PL2222311T3 (pl) | 2007-12-20 | 2013-08-30 | Nutricia Nv | Ciekły produkt zawierający nukleotydy/nukleozydy |
JP5397321B2 (ja) | 2009-06-09 | 2014-01-22 | 株式会社デンソー | 駐車支援システム |
-
2007
- 2007-06-26 WO PCT/NL2007/050306 patent/WO2009002145A1/en active Application Filing
-
2008
- 2008-06-20 AT AT08766833T patent/ATE538665T1/de active
- 2008-06-20 PL PL08766833T patent/PL2162019T3/pl unknown
- 2008-06-20 ES ES11195555T patent/ES2432345T3/es active Active
- 2008-06-20 PT PT111955555T patent/PT2436275E/pt unknown
- 2008-06-20 PL PL11195555T patent/PL2436275T3/pl unknown
- 2008-06-20 WO PCT/NL2008/050410 patent/WO2009002165A1/en active Application Filing
- 2008-06-20 EP EP08766833A patent/EP2162019B1/en not_active Revoked
- 2008-06-20 US US12/666,619 patent/US8283335B2/en active Active
- 2008-06-20 CN CN200880024527.0A patent/CN101742926B/zh active Active
- 2008-06-20 BR BRPI0813320-4A patent/BRPI0813320B1/pt active IP Right Grant
- 2008-06-20 EP EP11195555.5A patent/EP2436275B1/en active Active
- 2008-06-20 PT PT08766833T patent/PT2162019E/pt unknown
- 2008-06-20 DK DK11195555.5T patent/DK2436275T3/da active
- 2008-06-20 ES ES08766833T patent/ES2378176T3/es active Active
-
2009
- 2009-12-23 ZA ZA200909230A patent/ZA200909230B/xx unknown
-
2012
- 2012-09-14 US US13/620,382 patent/US8759319B2/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH06237734A (ja) * | 1991-11-06 | 1994-08-30 | Sanwa Kagaku Kenkyusho Co Ltd | 機能後退性疾患用食品組成物 |
US6835750B1 (en) * | 2000-05-01 | 2004-12-28 | Accera, Inc. | Use of medium chain triglycerides for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism II |
WO2007000529A2 (fr) * | 2005-05-16 | 2007-01-04 | Laboratoires Inneov | Traitement de la secheresse keratinique par des glycerides |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104305192A (zh) * | 2014-10-23 | 2015-01-28 | 贡岳松 | 改善老年痴呆症患者记忆的功能性食品及其制备方法 |
CN104305192B (zh) * | 2014-10-23 | 2016-05-04 | 贡岳松 | 改善老年痴呆症患者记忆的功能性食品及其制备方法 |
CN108712866A (zh) * | 2016-02-29 | 2018-10-26 | 朴启彰 | 健脑食品或健脑饮品与其施用方法 |
CN108777997A (zh) * | 2016-03-30 | 2018-11-09 | 雀巢产品技术援助有限公司 | 营养组合物及其用途 |
Also Published As
Publication number | Publication date |
---|---|
BRPI0813320B1 (pt) | 2018-08-07 |
US20110009357A1 (en) | 2011-01-13 |
ES2378176T3 (es) | 2012-04-09 |
ES2432345T3 (es) | 2013-12-02 |
BRPI0813320A2 (pt) | 2015-01-06 |
PT2436275E (pt) | 2013-10-31 |
US8759319B2 (en) | 2014-06-24 |
CN101742926B (zh) | 2017-06-09 |
PL2162019T3 (pl) | 2012-05-31 |
EP2436275A1 (en) | 2012-04-04 |
US8283335B2 (en) | 2012-10-09 |
DK2436275T3 (da) | 2013-10-28 |
ATE538665T1 (de) | 2012-01-15 |
US20130018012A1 (en) | 2013-01-17 |
WO2009002145A1 (en) | 2008-12-31 |
PL2436275T3 (pl) | 2013-12-31 |
ZA200909230B (en) | 2010-09-29 |
EP2436275B1 (en) | 2013-07-24 |
WO2009002165A1 (en) | 2008-12-31 |
EP2162019B1 (en) | 2011-12-28 |
EP2162019A1 (en) | 2010-03-17 |
PT2162019E (pt) | 2012-03-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101742926A (zh) | 用于改善脑功能的脂质组合物 | |
KR101424822B1 (ko) | 장쇄 다중불포화 지방산을 함유하는 영양 보충물 | |
KR100545630B1 (ko) | 필수 지방산과 생물활성 이황화물을 함유하는 치료 및식이요법 조성물 | |
US20010022980A1 (en) | Dietary supplement for individuals under stress | |
EP3077005B1 (en) | Composition comprising a uridine source and an omega-3 pufa for improving coordination, balance, grip strength or fine motor skills | |
JPWO2006033349A1 (ja) | 総合経腸栄養組成物 | |
CN102348469A (zh) | 富含omega-3的水包鱼油非口服营养乳状液 | |
US20160051506A1 (en) | Fat Emulsion for Artificially Feeding Seriously Ill Intensive Care Patients | |
JP2008247748A (ja) | 透析患者用栄養組成物 | |
EP3179868B1 (en) | Lipid composition for improving behaviour | |
AU2014260349B2 (en) | Nutritional composition comprising whey and hydrolyzed casein and uses thereof | |
US11077166B2 (en) | Nutritional supplements containing a peptide component and uses thereof | |
WO2011121150A1 (es) | Producto alimenticio enteral u oral especialmente destinado para la nutrición, prevención y mejora de alteraciones neurológicas, neurodegenerativas o trastornos cognitivos | |
JPH04152861A (ja) | 栄養補給用栄養組成物 | |
WO2008140064A1 (ja) | 生活習慣病の予防および改善のための栄養組成物 | |
JP3724740B2 (ja) | コエンザイムq10を含有する経管経腸栄養剤 | |
CA3132061A1 (en) | Ketone bodies enclosed in microbeads |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |